The Imugene share price has stormed 10% higher to 28.7 cents. This morning the biotech revealed that it has received Western Institutional Review Board approval to start a phase one clinical trial of a new cancer treatment. Imugene will look into the use of its oncolytic virotherapy candidate, Vaxinia, on multiple solid tumours.